Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
recombinant adenovirus-p53 SCH-58500 · 1 trial · 4 indications
| Name | Type | Description |
|---|---|---|
| recombinant adenovirus-p53 SCH-58500 | BIOLOGICAL | - |
DISEASE CHARACTERISTICS: Radiographic or surgical evidence of primary ovarian, fallopian tube, or peritoneal carcinoma Ascites cytologically positive for peritoneal carcinomatosis from recurrent or persistent ovarian, fallopian tube, or peritoneal carcinoma Must have ascites and tumor accessible by ...
Recombinant adenovirus-p53 SCH-58500 is an investigational therapy studied for the treatment of fallopian tube cancer, as well as ovarian cancer, primary peritoneal cavity cancer, and metastatic cancer. It was evaluated in a Phase 1 clinical trial in patients with these conditions.
Recombinant adenovirus-p53 SCH-58500 is being developed by Merck & Company, Inc., which is publicly traded under the ticker symbol MRK. The company sponsored a Phase 1 clinical trial of this investigational therapy.
Recombinant adenovirus-p53 SCH-58500 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, and no active trials are currently listed.
Recombinant adenovirus-p53 SCH-58500 has been studied in one completed clinical trial, identified as NCT00002960. This Phase 1 trial enrolled 59 female patients aged 18 years and older with fallopian tube cancer, ovarian cancer, primary peritoneal cavity cancer, or metastatic cancer.
Recombinant adenovirus-p53 SCH-58500 is designed to deliver the p53 gene via an adenovirus vector. The p53 gene encodes a tumor suppressor protein that plays a role in regulating cell division and preventing tumor growth.